The technology of monoclonal antibodies (Mabs) has been developed since the 1990s and is attracting more and more attention in China during the 21st century. While foreign Mabs dominate the Chinese market domestic universities and companies are taking efforts to catch up with the strong support from Chinese government. The first monoclonal antibody product was introduced by the Chinese local producer in 1999, and presently seven products are listed, of which three are humanized products. There are several technical constraints that are affecting the development of monoclonal antibodies in China: limitations to the number of drug targets, restricted biological diffusion, limitations to administration routes, and species-specific issues, as well as China's own limitations in production and R&D capabilities. This article provides suggestions relevant for the Chinese development of monoclonal antibodies. In the long run China is expected to catch up with its own technology roadmap and market opportunity.